Observational studyJournal of Korean medical science2022

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.

Sujin Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.